Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma

Glioblastomas, accounting for approximately 50% of gliomas, comprise the most aggressive, highly heterogeneous, and malignant brain tumors. The objective of this study was to develop and evaluate a new targeted therapy, i.e., highly potent natural compound verrucarin A (Ver-A), delivered with monocl...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Kai, Si, Yingnan, Guan, Jia-Shiung, Zhou, Zhuoxin, Kim, Seulhee, Kim, Taehyun, Shan, Liang, Willey, Christopher D., Zhou, Lufang, Liu, Xiaoguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773723/
https://www.ncbi.nlm.nih.gov/pubmed/35052809
http://dx.doi.org/10.3390/biomedicines10010130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773723/
https://www.ncbi.nlm.nih.gov/pubmed/35052809
http://dx.doi.org/10.3390/biomedicines10010130

Ejemplares similares